The essential precaution is patient-specific screening, not a blanket ban on anesthetic or epinephrine. Before an aesthetic procedure, assess the planned drug, total dose, organ function, cardiovascular status, medications, treatment site, pregnancy or lactation status, and the patient’s ability to recognize and report systemic symptoms. Severe liver disease, significant cardiovascular disease, uncontrolled hypertension or hyperthyroidism, pheochromocytoma, compromised tissue perfusion, and interacting medications require particular caution or medical review.
Local anesthetic safety depends primarily on the correct drug, dose, route, and patient selection. Epinephrine can improve hemostasis and prolong anesthesia, but it may produce dangerous cardiovascular effects or ischemia in susceptible patients; neither should be used without appropriate monitoring and emergency preparedness.
Screen for Local Anesthetic Risk
Confirm the anesthetic class
Amide anesthetics—such as lidocaine, mepivacaine, and bupivacaine—are primarily metabolized in the liver. Severe hepatic impairment can reduce clearance and increase the risk of accumulation and local anesthetic systemic toxicity, so clinicians may need a reduced dose, greater spacing between doses, or specialist advice.
Ester anesthetics are mainly hydrolyzed by plasma esterases rather than being primarily renally excreted. Severe renal disease may still increase risk through impaired elimination of metabolites and greater physiological vulnerability, but it is inaccurate to treat severe renal failure as a universal contraindication to every ester anesthetic.
Investigate previous reactions
Ask about prior reactions to local anesthetics, preservatives, sulfites, latex, and injectable products. A reported “allergy” may have been vasovagal syncope, anxiety, palpitations from epinephrine, or a reaction to a preservative rather than to the anesthetic itself.
A suspected true allergy requires careful documentation and selection of an appropriate alternative. Do not simply re-administer the same product without clarification.
Calculate cumulative dose
The clinician must calculate the total dose from all anesthetic sources, including topical products, infiltration, nerve blocks, and repeat injections. Maximum doses vary by agent, concentration, route, patient age, body size, and organ function.
Use the lowest effective dose and avoid automatic dose limits copied from another product or procedure. Frail, elderly, low-body-weight, or medically compromised patients may require additional reduction.
Recognize systemic toxicity risk
Early symptoms of local anesthetic systemic toxicity can include circumoral numbness, metallic taste, tinnitus, dizziness, agitation, or unusual drowsiness. Severe toxicity can progress to seizures, respiratory depression, dangerous arrhythmias, cardiovascular collapse, and cardiac arrest.
Treatment facilities should have trained staff, monitoring appropriate to the procedure, resuscitation equipment, and a defined emergency pathway. Suspected toxicity requires immediate cessation of injection and emergency management according to current local protocols.
Assess Epinephrine Before Adding It
Understand why epinephrine is used
Dilute epinephrine can produce local vasoconstriction, reduce bleeding, slow systemic absorption, and extend the duration of anesthesia. Common concentrations include 1:100,000 and 1:200,000, but the appropriate concentration and total amount depend on the procedure and patient.
The benefit is not automatically greater at higher concentrations. Use the smallest effective amount, inject incrementally, aspirate when appropriate, and observe the patient for cardiovascular symptoms.
Identify high-risk cardiovascular conditions
Require careful assessment or medical clearance for patients with:
- Uncontrolled hypertension
- Unstable angina or significant ischemic heart disease
- Serious uncontrolled arrhythmias
- Decompensated heart failure
- Recent major cardiovascular events
- Severe peripheral arterial disease or compromised local perfusion
Controlled hypertension or stable cardiovascular disease is generally a relative precaution, not an automatic prohibition. The decision should account for disease control, epinephrine dose, procedure intensity, and available monitoring.
Screen for endocrine and vascular conditions
Uncontrolled hyperthyroidism and pheochromocytoma can increase sensitivity to catecholamines and present substantial risk with epinephrine. These conditions require specialist assessment and are commonly treated as contraindications to elective epinephrine-containing injections until adequately managed.
Avoid or carefully reconsider epinephrine in tissue with poor arterial supply, severe peripheral vascular disease, or existing ischemia. Areas with terminal or vulnerable circulation require particular caution, especially with circumferential or high-volume injections.
Do not rely on an arbitrary universal maximum
A frequently cited ceiling of 1 mg of epinephrine should not be treated as a universal aesthetic-practice target or permission to administer that amount. Safe dosing depends on the patient, formulation, route, and procedure; many patients require far less.
Document the concentration and total microgram dose. A concentration written as a ratio—such as 1:100,000—should be converted carefully to the actual volume and dose to prevent calculation errors.
Review Medication Interactions
Beta-blockers and cardiovascular medicines
Nonselective beta-blockers may intensify vasoconstrictive responses and contribute to hypertension or reflex bradycardia when epinephrine is administered. This is a risk-management issue, not a reason to stop prescribed medication independently.
Record the specific drug, dose, indication, and cardiovascular history. Discuss significant concerns with the prescribing clinician and use the lowest effective epinephrine dose if treatment proceeds.
Tricyclic antidepressants and monoamine oxidase inhibitors
Tricyclic antidepressants may increase cardiovascular responses to sympathomimetics. Monoamine oxidase inhibitors are often listed as contraindications, but the clinical interaction is not always an absolute prohibition with modern dilute local use.
Because evidence and product labeling differ, avoid categorical decisions based only on a medication name. Confirm the product information, assess the patient’s cardiovascular status, and obtain medical advice when risk is unclear.
Drugs affecting neuromuscular transmission
Myasthenia gravis, Lambert–Eaton syndrome, other neuromuscular disorders, and drugs such as aminoglycoside antibiotics can increase concern about neuromuscular weakness. These conditions are particularly relevant when treatment involves substantial local anesthetic exposure, deep blocks, sedation, or other agents that may impair respiration.
They are not automatically contraindications to every superficial aesthetic injection. They do, however, justify individualized assessment and a lower threshold for specialist input.
Antiplatelet and supplement use
Aspirin, NSAIDs, anticoagulants, and some supplements may increase bruising or bleeding. Fish-oil supplements should not automatically be treated as a major bleeding contraindication, but the complete medication and supplement history should be documented.
Do not advise patients to stop prescribed antiplatelet or anticoagulant therapy without the prescriber’s direction. The bleeding risk must be balanced against the potentially serious risk of thrombosis.
Assess the Treatment Site and Patient Context
Do not inject through active disease
Avoid elective injection through active infection, cellulitis, significant inflammation, open wounds, or untreated herpes lesions. Infection can spread, healing can be impaired, and local inflammation can make adverse reactions harder to recognize.
Postpone treatment until the condition has resolved or obtain appropriate medical assessment. This precaution is separate from whether the anesthetic itself is pharmacologically safe.
Consider pregnancy and breastfeeding correctly
Pregnancy and breastfeeding are strong reasons to defer elective aesthetic procedures, primarily because the procedure is nonessential and safety data for many cosmetic interventions are limited. They are not universal pharmacological contraindications to every medically necessary use of local anesthetic.
If treatment is clinically necessary, the clinician should select an appropriate agent and dose in consultation with the patient’s obstetric or medical team. Epinephrine use likewise requires individualized assessment rather than an automatic assumption of absolute prohibition.
Evaluate neurological and functional history
Ask about seizure disorders, significant neuropathy, neuromuscular disease, respiratory compromise, and previous difficulty tolerating injections. These factors may alter the risk of toxicity, weakness, anxiety-related events, or impaired recovery.
A patient who cannot reliably report early toxicity symptoms may require additional monitoring or a different treatment plan.
Separate anesthetic screening from energy-based treatment screening
Laser, radiofrequency, HIFU, and other energy-based treatments have additional contraindications that do not arise from local anesthetics or epinephrine. These may include active infection, open wounds, photosensitizing medication, relevant photosensitivity, recent isotretinoin exposure according to current product and professional guidance, and treatment over unintended tattoos.
Do not combine all contraindications into one generic checklist. Screen separately for drug risk, injection-site risk, and device-specific risk.
Understanding the Trade-offs
Epinephrine improves anesthesia but adds cardiovascular risk
Epinephrine can reduce bleeding and delay systemic uptake of the anesthetic. The trade-off is possible tachycardia, palpitations, hypertension, anxiety, arrhythmia, or local ischemia.
The safest approach is not to eliminate epinephrine in every patient. It is to use it only when its benefits matter, at the lowest effective dose, with appropriate observation.
“Absolute” and “relative” contraindications are not interchangeable
Pheochromocytoma, uncontrolled hyperthyroidism, severe untreated cardiovascular instability, and severely compromised local perfusion may make epinephrine inappropriate for elective treatment. Controlled hypertension, stable heart disease, breastfeeding, or use of an MAO inhibitor may instead require individualized risk assessment.
Product labeling, national guidance, and the patient’s medical circumstances should determine the final decision. When the risk cannot be characterized confidently, defer treatment and obtain medical advice.
More anesthetic is not necessarily safer or better
Repeated top-ups, multiple treated areas, and combining topical and injectable anesthetics can create an unrecognized cumulative dose. Higher epinephrine concentrations may increase adverse effects without providing proportional benefit.
Record the product, concentration, volume, calculated dose, injection sites, time of administration, and any additional anesthetic used during the session.
Screening cannot replace emergency readiness
Even a healthy patient can experience an unexpected reaction, intravascular injection, vasovagal episode, or toxicity. Screening reduces risk but does not eliminate it.
Clinicians should work within their training and authorization, use suitable monitoring, maintain emergency equipment, and have clear escalation procedures.
Making the Right Choice for Your Goal
Use the screening findings to decide whether to proceed, modify the plan, seek medical clearance, or postpone treatment.
- If your primary focus is preventing anesthetic toxicity: Verify the anesthetic class, calculate the cumulative dose, adjust for liver or kidney impairment and frailty, and monitor for early neurological or cardiovascular symptoms.
- If your primary focus is cardiovascular safety: Identify uncontrolled hypertension, unstable heart disease, serious arrhythmia, hyperthyroidism, pheochromocytoma, and interacting medicines before using epinephrine.
- If your primary focus is protecting the treatment site: Do not inject through infection, active inflammation, open wounds, herpes lesions, or tissue with significantly impaired circulation.
- If your primary focus is managing medication risk: Review beta-blockers, antidepressants, MAO inhibitors, anticoagulants, antiplatelet drugs, supplements, and aminoglycosides without stopping prescribed therapy independently.
- If your primary focus is treating during pregnancy or breastfeeding: Defer elective aesthetic treatment whenever practical and obtain individualized medical advice before any nonessential procedure.
- If your primary focus is device-based aesthetic treatment: Complete a separate laser, HIFU, or radiofrequency screening process for photosensitivity, infection, medication exposure, scarring history, and device-specific hazards.
A structured, individualized assessment is the most reliable safeguard against preventable complications from local anesthetics and epinephrine.
Summary Table:
| Category | Key Considerations | Management |
|---|---|---|
| Anesthetic Class | Amides (lidocaine, etc.) metabolized in liver; esters via plasma esterases | Adjust dose in hepatic/renal impairment; monitor for toxicity |
| Previous Reactions | Allergy vs. vasovagal/anxiety; preservatives | Document; choose alternative; avoid re-administering |
| Cumulative Dose | All sources: topical, infiltration, blocks | Calculate total; use lowest effective dose |
| Systemic Toxicity | Early: numbness, tinnitus; severe: seizures, arrest | Emergency readiness; stop injection if suspected |
| Epinephrine Use | Vasoconstriction improves hemostasis; cardiovascular risks | Use lowest effective dose; screen for hypertension, arrhythmias |
| Cardiovascular Conditions | Uncontrolled hypertension, unstable angina, etc. | Medical clearance; caution with stable disease |
| Endocrine & Vascular | Hyperthyroidism, pheochromocytoma; poor perfusion | Avoid epinephrine; specialist assessment |
| Medications | Beta-blockers, TCAs, MAOIs, anticoagulants | Individualize; consult prescriber; balance risks |
| Treatment Site | Active infection, inflammation, open wounds | Defer treatment until resolved |
| Pregnancy/ breastfeeding | Non-essential; limited safety data | Defer elective procedures; individualize if necessary |
| Neurological History | Seizures, neuromuscular disease | Monitor; adjust plan |
| Device-Specific | Laser/RF/HIFU separate contraindications | Separate screening for device risks |
Ensure Safety in Every Aesthetic Procedure with BELIS
At BELIS, we prioritize patient safety and treatment efficacy. Our advanced aesthetic equipment is designed to support your clinical excellence. Whether you're a clinic or premium salon, our portfolio includes state-of-the-art laser systems, IPL, body sculpting devices, and more, all backed by comprehensive training and support.
Ready to elevate your practice?
Contact us today to learn how BELIS can enhance your treatments, ensure compliance, and boost patient satisfaction. Let's shape the future of aesthetic medicine together!